IL193773A0 - A peptide which binds to an erythropoietin receptor and pharmaceutical compositions containing the same - Google Patents
A peptide which binds to an erythropoietin receptor and pharmaceutical compositions containing the sameInfo
- Publication number
- IL193773A0 IL193773A0 IL193773A IL19377308A IL193773A0 IL 193773 A0 IL193773 A0 IL 193773A0 IL 193773 A IL193773 A IL 193773A IL 19377308 A IL19377308 A IL 19377308A IL 193773 A0 IL193773 A0 IL 193773A0
- Authority
- IL
- Israel
- Prior art keywords
- binds
- peptide
- same
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 108010075944 Erythropoietin Receptors Proteins 0.000 title 1
- 102100036509 Erythropoietin receptor Human genes 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78056806P | 2006-03-09 | 2006-03-09 | |
| EP06004833 | 2006-03-09 | ||
| US74751506P | 2006-05-17 | 2006-05-17 | |
| EP06010174 | 2006-05-17 | ||
| PCT/EP2007/002068 WO2007101698A2 (en) | 2006-03-09 | 2007-03-09 | Modified molecules which promote hematopoiesis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL193773A0 true IL193773A0 (en) | 2011-08-01 |
Family
ID=38475217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL193773A IL193773A0 (en) | 2006-03-09 | 2008-08-31 | A peptide which binds to an erythropoietin receptor and pharmaceutical compositions containing the same |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20090281278A1 (enExample) |
| EP (1) | EP2007791A2 (enExample) |
| JP (1) | JP2009529509A (enExample) |
| AU (1) | AU2007222526A1 (enExample) |
| BR (1) | BRPI0709014A2 (enExample) |
| CA (1) | CA2680228A1 (enExample) |
| IL (1) | IL193773A0 (enExample) |
| MX (1) | MX2008011389A (enExample) |
| SG (1) | SG170086A1 (enExample) |
| WO (1) | WO2007101698A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7589063B2 (en) | 2004-12-14 | 2009-09-15 | Aplagen Gmbh | Molecules which promote hematopoiesis |
| JP2009242372A (ja) * | 2008-03-11 | 2009-10-22 | Yokohama City Univ | 均一な糖鎖構造を有するエリスロポエチン誘導体 |
| CN102238966B (zh) | 2008-12-06 | 2014-08-06 | 贝朗医疗有限公司 | 转运介导的胶体药用化合物 |
| US9056085B2 (en) * | 2009-02-03 | 2015-06-16 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| US9051548B2 (en) | 2009-02-03 | 2015-06-09 | Children's Medical Center Corporation | Methods for enhancing hematopoietic stem/progenitor cell engraftment |
| WO2010136242A1 (de) * | 2009-03-31 | 2010-12-02 | B. Braun Melsungen Ag | Verknüpfungsprodukte aminierter polysaccharide |
| WO2011012306A2 (en) | 2009-07-30 | 2011-02-03 | Aplagen Gmbh | Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis |
| US9517257B2 (en) | 2010-08-10 | 2016-12-13 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| US9850296B2 (en) | 2010-08-10 | 2017-12-26 | Ecole Polytechnique Federale De Lausanne (Epfl) | Erythrocyte-binding therapeutics |
| CN104231067B (zh) * | 2013-06-07 | 2017-08-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 促红细胞生成素模拟肽化学二聚体及其用途 |
| US10046056B2 (en) | 2014-02-21 | 2018-08-14 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10953101B2 (en) | 2014-02-21 | 2021-03-23 | École Polytechnique Fédérale De Lausanne (Epfl) | Glycotargeting therapeutics |
| US10946079B2 (en) | 2014-02-21 | 2021-03-16 | Ecole Polytechnique Federale De Lausanne | Glycotargeting therapeutics |
| EP3909603A1 (en) | 2014-02-21 | 2021-11-17 | Ecole Polytechnique Fédérale de Lausanne (EPFL) | Glycotargeting therapeutics |
| US11253579B2 (en) | 2017-06-16 | 2022-02-22 | The University Of Chicago | Compositions and methods for inducing immune tolerance |
| JP2021528371A (ja) | 2018-05-09 | 2021-10-21 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 免疫寛容に関する組成物および方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3924746A1 (de) * | 1989-07-26 | 1991-01-31 | Behringwerke Ag | Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper |
| US5747446A (en) * | 1994-03-22 | 1998-05-05 | Beth Israel Deaconess Medical Center | Modified polypeptides with increased biological activity |
| CN1192748A (zh) * | 1995-06-07 | 1998-09-09 | 奥尔托药品有限公司 | 与红细胞生成素受体结合的化合物和肽 |
| AU2003215732B2 (en) * | 2002-03-01 | 2009-12-17 | Immunomedics, Inc. | Internalizing anti-CD74 antibodies and methods of use |
| WO2004002424A2 (en) * | 2002-06-28 | 2004-01-08 | Centocor, Inc. | Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses |
| WO2004101600A2 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel poly(ethylene glycol) modified compounds and uses thereof |
| US20070275871A1 (en) * | 2003-08-28 | 2007-11-29 | Biorexis Technology, Inc. | Epo Mimetic Peptides and Fusion Proteins |
| JP2008519589A (ja) * | 2004-11-10 | 2008-06-12 | アプラゲン ゲーエムベーハー | 造血を促進する分子 |
| WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| JP2008546732A (ja) * | 2005-06-23 | 2008-12-25 | アプラゲン ゲーエムベーハー | 多価化合物 |
-
2007
- 2007-03-09 MX MX2008011389A patent/MX2008011389A/es not_active Application Discontinuation
- 2007-03-09 AU AU2007222526A patent/AU2007222526A1/en not_active Abandoned
- 2007-03-09 SG SG201101682-1A patent/SG170086A1/en unknown
- 2007-03-09 CA CA002680228A patent/CA2680228A1/en not_active Abandoned
- 2007-03-09 EP EP07711874A patent/EP2007791A2/en not_active Withdrawn
- 2007-03-09 JP JP2008557672A patent/JP2009529509A/ja active Pending
- 2007-03-09 BR BRPI0709014-5A patent/BRPI0709014A2/pt not_active IP Right Cessation
- 2007-03-09 US US12/281,565 patent/US20090281278A1/en not_active Abandoned
- 2007-03-09 WO PCT/EP2007/002068 patent/WO2007101698A2/en not_active Ceased
-
2008
- 2008-08-31 IL IL193773A patent/IL193773A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0709014A2 (pt) | 2011-06-21 |
| CA2680228A1 (en) | 2007-09-13 |
| JP2009529509A (ja) | 2009-08-20 |
| WO2007101698A3 (en) | 2008-08-21 |
| US20090281278A1 (en) | 2009-11-12 |
| AU2007222526A1 (en) | 2007-09-13 |
| WO2007101698A2 (en) | 2007-09-13 |
| EP2007791A2 (en) | 2008-12-31 |
| MX2008011389A (es) | 2009-01-26 |
| SG170086A1 (en) | 2011-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL193773A0 (en) | A peptide which binds to an erythropoietin receptor and pharmaceutical compositions containing the same | |
| IL193775A0 (en) | Pharmaceutical compositions containing natalizumab | |
| EP2001498A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| IL194176A0 (en) | Pharmaceutical compositions | |
| GB0713625D0 (en) | Pharmaceutical compositions | |
| IL194429A0 (en) | Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same | |
| IL196168A0 (en) | Biaryl compounds and pharmaceutical compositions containing the same | |
| EP2124556A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| IL232825A0 (en) | Therapeutic compositions of fusion proteins | |
| ZA200807721B (en) | Anti-cancer pharmaceutical composition | |
| AU2013257508A1 (en) | Pharmaceutical compositions | |
| HUE063083T2 (hu) | Nilotinibet vagy sóját tartalmazó gyógyszerészeti készítmények | |
| EP2056835A4 (en) | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| PL2005958T3 (pl) | Kompozycja farmaceutyczna do stosowania zewnętrznego | |
| HUE044237T2 (hu) | Kortexolon-17-alfa-propionátot tartalmazó gyógyszerészeti kompozíciók | |
| GB0608724D0 (en) | Novel Pharmaceutical Compositions | |
| GB0610322D0 (en) | Novel pharmaceutical compositions | |
| IL184631A0 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING A Wht3a PROTEIN | |
| EP2124959A4 (en) | PHARMACEUTICAL COMPOSITION | |
| ZA200808768B (en) | Pharmaceutical composition containing the NMB0606 protein | |
| EP2204173A4 (en) | PHARMACEUTICAL COMPOSITION HAVING ANTIDIABETIC EFFECT | |
| EP2091959A4 (en) | IMPROVED PEPTIDE COMPOSITION | |
| HU0700755D0 (en) | Pharmaceutical compositions containing capsaicionid | |
| GB0619768D0 (en) | Pharmaceutical composition comprising antibodies | |
| GB0622964D0 (en) | Pharmaceutical compositions |